Chinook Therapeutics Closes Merger with Aduro Biotech and Completes $115 Million Private Placement Financing - Seite 3
Cautionary Note on Forward-Looking Statements
Certain of the statements made in this press release are forward looking, including those relating to Chinook’s business, future operations, advancement of its product candidates and product
pipeline, clinical development of its product candidates, including expectations regarding timing of initiation and results of clinical trials and sufficiency of its cash resources. In some cases,
you can identify these statements by forward-looking words such as “may,” “will,” “continue,” “anticipate,” “intend,” “could,” “project,” “expect” or the negative or plural of these words or
similar expressions. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially
from those anticipated, including, but not limited to, our ability to develop and commercialize our product candidates, whether results of early clinical trials or preclinical studies will be
indicative of the results of future trials, our ability to obtain and maintain regulatory approval of our product candidates, our ability to operate in a competitive industry and compete
successfully against competitors that may be more advanced or have greater resources than we do, our ability to obtain and adequately protect intellectual property rights for our product candidates
and the effects of COVID-19 on our clinical programs and business operations. Many of these risks are described in greater detail in the proxy statement/prospectus filed by Aduro with the SEC
relating to the merger. Any forward-looking statements in this press release speak only as of the date of this press release. Chinook assumes no obligation to update forward-looking statements
whether as a result of new information, future events or otherwise, after the date of this press release.
Contact: |
Noopur Liffick |
Vice President, Investor Relations & Corporate Communications |
510-809-2465 |
investors@chinooktx.com |
media@chinooktx.com |